InterMune, Inc. Reports Preliminary Fourth Quarter 2013 Esbriet® (pirfenidone) Revenue And Recent Business Highlights

BRISBANE, Calif., Jan. 9, 2014 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced unaudited revenue for the fourth quarter and year ended December 31, 2013. The company also provided updated 2013 expense guidance, highlighted recent progress in its commercial and other business activities and provided forward-looking guidance for 2014 revenue and expenses.

Help employers find you! Check out all the jobs and post your resume.